These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 12646950

  • 1. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
    Zhu Z, Hattori K, Zhang H, Jimenez X, Ludwig DL, Dias S, Kussie P, Koo H, Kim HJ, Lu D, Liu M, Tejada R, Friedrich M, Bohlen P, Witte L, Rafii S.
    Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
    Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF.
    Clin Cancer Res; 2003 Apr; 9(4):1323-32. PubMed ID: 12684400
    [Abstract] [Full Text] [Related]

  • 3. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z.
    Cancer Res; 2001 Oct 01; 61(19):7002-8. PubMed ID: 11585724
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.
    Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, Bohlen P, Hicklin D, Zhu Z.
    Leuk Lymphoma; 2004 Sep 01; 45(9):1887-97. PubMed ID: 15223651
    [Abstract] [Full Text] [Related]

  • 5. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y, Zhong Z, Huber J, Bassi R, Finnerty B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H, Mangalampalli VR, Ludwig DL, Tonra JR, Hicklin DJ.
    Clin Cancer Res; 2006 Nov 01; 12(21):6573-84. PubMed ID: 17085673
    [Abstract] [Full Text] [Related]

  • 6. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
    Li R, Xiong DS, Shao XF, Liu J, Xu YF, Xu YS, Liu HZ, Zhu ZP, Yang CZ.
    Acta Pharmacol Sin; 2004 Oct 01; 25(10):1292-8. PubMed ID: 15456530
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
    Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, Bohlen P, Witte L.
    Cancer Res; 1998 Aug 01; 58(15):3209-14. PubMed ID: 9699643
    [Abstract] [Full Text] [Related]

  • 8. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
    Lu D, Shen J, Vil MD, Zhang H, Jimenez X, Bohlen P, Witte L, Zhu Z.
    J Biol Chem; 2003 Oct 31; 278(44):43496-507. PubMed ID: 12917408
    [Abstract] [Full Text] [Related]

  • 9. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
    Miao HQ, Hu K, Jimenez X, Navarro E, Zhang H, Lu D, Ludwig DL, Balderes P, Zhu Z.
    Biochem Biophys Res Commun; 2006 Jun 23; 345(1):438-45. PubMed ID: 16682007
    [Abstract] [Full Text] [Related]

  • 10. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.
    Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, Wu Y, Chadburn A, Hyjek E, Gill M, Hicklin DJ, Witte L, Moore MA, Rafii S.
    J Clin Invest; 2000 Aug 23; 106(4):511-21. PubMed ID: 10953026
    [Abstract] [Full Text] [Related]

  • 11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 12. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
    Nakabayashi M, Morishita R, Nakagami H, Kuba K, Matsumoto K, Nakamura T, Tano Y, Kaneda Y.
    Diabetologia; 2003 Jan 15; 46(1):115-23. PubMed ID: 12637990
    [Abstract] [Full Text] [Related]

  • 13. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.
    Cancer Res; 2000 Sep 15; 60(18):5117-24. PubMed ID: 11016638
    [Abstract] [Full Text] [Related]

  • 14. [Effect of monoclonal antibody against extracellular domain III of vascular endothelial growth factor receptor KDR on proliferation of vascular endothelial cells].
    Li R, Xiong DS, Shao XF, Xu YF, Zhu ZP, Yang CZ.
    Zhonghua Zhong Liu Za Zhi; 2005 Apr 15; 27(4):209-12. PubMed ID: 15949417
    [Abstract] [Full Text] [Related]

  • 15. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.
    Cancer Res; 2000 Apr 15; 60(8):2178-89. PubMed ID: 10786682
    [Abstract] [Full Text] [Related]

  • 16. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB.
    J Mol Biol; 1999 Nov 05; 293(4):865-81. PubMed ID: 10543973
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M.
    Clin Cancer Res; 2005 Jul 01; 11(13):4934-40. PubMed ID: 16000592
    [Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor as a marker of tumor endothelium.
    Brekken RA, Huang X, King SW, Thorpe PE.
    Cancer Res; 1998 May 01; 58(9):1952-9. PubMed ID: 9581838
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
    Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.
    Oncogene; 2005 Jan 27; 24(5):790-800. PubMed ID: 15592523
    [Abstract] [Full Text] [Related]

  • 20. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS.
    Mol Cancer Res; 2002 Dec 27; 1(2):89-95. PubMed ID: 12496355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.